The focus for the use of bioinformatics resources in the pharmaceutical industry is increasingly moving from the vigorous pursuit of intellectual property towards exploration of pre-competitive collaborations and engagement with the public domain. In this article, we discuss the rationale for these changes and the associated challenges, and also propose new areas of public–private collaboration in computational biology and chemistry that could enhance drug discovery in academia and industry.
- Michael R. Barnes
- Lee Harland
- Cory R. Brouwer
